MedPath

ALREX

ALREX loteprednol etabonate ophthalmic suspension, 0.2%

Approved
Approval ID

95188fb4-03b6-46ac-a601-41cb82ebde40

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 10, 2012

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

loteprednol etabonate

PRODUCT DETAILS

NDC Product Code54868-4277
Application NumberNDA020803
Marketing CategoryC73594
Route of AdministrationOPHTHALMIC
Effective DateSeptember 10, 2012
Generic Nameloteprednol etabonate

INGREDIENTS (9)

EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT
GLYCERINInactive
Code: PDC6A3C0OX
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
LOTEPREDNOL ETABONATEActive
Quantity: 2 mg in 1 mL
Code: YEH1EZ96K6
Classification: ACTIB
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
POVIDONEInactive
Code: FZ989GH94E
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
TYLOXAPOLInactive
Code: Y27PUL9H56
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ALREX - FDA Drug Approval Details